Bristol Expands R&D In India Through Biocon Deal
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb is expanding its research and development presence in India through a deal with Bangalore-based Biocon on discovery research work involving medicinal chemistry, biology and drug metabolism, the firms announced March 14
You may also be interested in...
Biocon Partners With Biotech Startup In Latest India-U.S. Deal
NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases
Biocon Partners With Biotech Startup In Latest India-U.S. Deal
NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases
GSK/Ranbaxy Deal Gives Indian Firm Greater Development Charge
Under expansion of 2003 deal, Indian firm will take targets to proof of concept, gaining milestones, possible royalties.